Torley Helen 4

4 · HALOZYME THERAPEUTICS, INC. · Filed Jul 9, 2026

AI-generated summary of this filing

Updated Jul 9, 2026

Halozyme (HALO) CEO Helen Torley Exercises Options and Sells Shares

What Happened

Helen Torley, President & CEO and a director of Halozyme Therapeutics (HALO), exercised 1,923 stock options on July 8, 2026 at $12.07 per share (total cost $23,211) and sold the 1,923 resulting common shares in two open-market transactions the same day.
Sales details: 888 shares sold at $79.28 for $70,397, and 1,035 shares sold at $80.19 for $82,994, totaling approximately $153,391. These transactions were reported on a Form 4 filed July 9, 2026.

Key Details

Transaction date: July 8, 2026; Form 4 filed July 9, 2026 (timely).
Exercise: 1,923 shares exercised at $12.07 (total $23,211).
Sales: 888 @ $79.28 (≈ $70,397); 1,035 @ $80.19 (≈ $82,994); combined proceeds ≈ $153,391.
Net cash realized before taxes/fees (approximate): $153,391 − $23,211 = ~$130,180.
Shares owned after the transaction: not disclosed in the provided filing excerpt.
Notable footnotes:
- Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 21, 2025 (F1).
- The sales prices reported are weighted averages; price ranges and breakdowns are available from the issuer or SEC staff on request (F2, F3).
- The exercised options were from a grant dated February 22, 2017 with a standard 4‑year vesting schedule; the options have a ten-year term expiring Feb 2027 (F4, F1).

Context

This was effectively a cashless exercise: options were exercised and the acquired shares were sold the same day. That is a common way for insiders to realize gains from vested options.
Because the sales were executed under a pre-established 10b5-1 plan, they were preplanned transactions and do not necessarily indicate a change in the CEO’s view of the company.
For full ownership details or the exact per-share breakdown within the weighted averages, consult the complete Form 4 on EDGAR.

Form 4

Period: 2026-07-08

DirectorPRESIDENT AND CEO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-07-08$12.07/sh+1,923$23,211→ 769,703 total
Sale
Common Stock
[F1][F2]
2026-07-08$79.28/sh−888$70,397→ 768,815 total
Sale
Common Stock
[F1][F3]
2026-07-08$80.19/sh−1,035$82,994→ 767,780 total
Exercise/Conversion
Option to Purchase Common Stock
[F1][F4]
2026-07-08$12.07/sh−1,923$23,211→ 0 total
Exercise: $12.07Exp: 2027-02-22→ Common Stock (1,923 underlying)

Footnotes (4)

[F1]The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
[F2]Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.710 to $79.700. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $79.710 to $80.490. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.

Signature

/s/ James R. Oehler, Attorney-in-Fact|2026-07-09

1 file